BioXcel Therapeutics Inc (BTAI)

[conix]

BTAI Investment HIGHLIGHTS:

*"Unleashing the Power of Artificial Intelligence Across the Entire R&D Value Chain"

*Later-Stage Pipeline with Multiple Near-Term Milestones

*BXCL501 - First in Class Sublingual Thin Film for Acute Treatment of Agitation(Growing Global Healthcare Issue)

*'Agitation' includes Schizophrenia; Dementia; Delirium; Opiod Withdrawal

*Delivery is 'Thin Film/Mouth' - FDA Fast Track Designation - Rapid Onset; Good Safety; Easy to Administer; Non-Invasive

*Phase 2 Readout 3rd Quarter; Anticipated Phase 3 before End of Year 2019

*BXCL701 - First in Class Oral IO Therapy Targeting Pancreatic Cancer and tNEPC

*Biomarker Driven Development Advanced Pancreatic Cancer with Potential Breakthrough Designation

*Cash/Equivalents: $36.3 million as of 3/31/2019

*Major Shareholders: Artemis; Fidelity; DNCA Finance

*Research Coverage includes Barclays, BMO and UBS


BioXcel Therapeutics Inc. - Company Background:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Market Capitalization: $175 million
Range - 52 week: $14.79 - $2.41
Current Price: $10.+
Trades on: Nasdaq Capital Markets
Ticker Symbol: BTAI

Website: www.bioxceltherapeutics.com